Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case Report

Successful management of post-COVID-19 acanthamoebic encephalitis

Govinda Siripurapu a, Sameer Abdul Samad b,*, Saman Fatima a, Naveet Wig b, M.V. Padma Srivastava a

a Department of Neurology, AIIMS New Delhi, Delhi, India
b Department of Medicine, AIIMS New Delhi, Delhi, India

ABSTRACT

Acanthamoebic encephalitis is a rare and highly fatal disease that has no standard management protocol. Coronavirus disease 2019 (COVID-19) causes immune dysfunction and may predispose patients to this infection. The present study describes successful management of acanthamoebic encephalitis in a young male who recently recovered from COVID-19 using a combination of medical and surgical approaches. A combination of miltefosine with other agents with trophicidal and cysticidal activities should be used in the regimen. Surgical excision of the abscess should be undertaken whenever feasible.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Background

Acanthamoebae are free living amoebae ubiquitously present in the environment. Human exposure to this organism is quite frequent, as reflected by its high seroprevalence of more than 80% in the general population (Brindley et al., 2009). Both trophozoites and cysts can enter the body via contact lens use, skin wounds, or inhalation and can hematogenously disseminate to the central nervous system (Acanthamoeba - Granulomatous Amoebic Encephalitis (GAE); Keratitis | Acanthamoeba | Parasites | CDC, n.d.). Dissemination occurs in individuals with immune dysfunction; however, coronavirus disease 2019 (COVID-19)-induced predisposition of individuals to acanthamoebic encephalitis has not been reported previously.

Acanthamoebic encephalitis rapidly progresses over days and has a mortality rate of 97% – 98% (Kot et al., 2018). Optimal approach to the treatment of this disease is uncertain. Only a few reports of successful treatment with combination drug therapy are available in the literature; the following drugs were used in various combinations for variable durations ranging from two weeks to several months: miltefosine, fluconazole, ketoconazole, trimethoprim-sulfamethoxazole, sulfadiazine, metronidazole, rifampicin, vancomycin, ceftriaxone, dexamethasone, albendazole, carbamazepine, pentamidine, liposomal amphotericin B, fluconazole, and voriconazole (Kot et al., 2021).

The present study reports a case of acanthamoebic encephalitis in a patient after recovery from COVID-19 that was successfully managed with a combination of the medical and surgical approaches.

Case Report

A 32-year-old man with no previously known comorbidities was diagnosed with moderate COVID-19 and received a five-day course of methylprednisolone and oxygen supplementation along with other supportive measures; the patient remained asymptomatic for six weeks. One day, the patient nearly got into an accident while driving because he was unable to correctly estimate the distance to a nearby vehicle. Three days after the incident, the patient developed a weakness of the right side of the body and facial deviation to the left, which rapidly progressed to a maximum within four days. Magnetic resonance imaging (MRI) of the brain showed a multifocal variable-sized ring and enhancing nodular lesions in the bilateral hemispheres (Figure 1A).

Cerebrospinal fluid (CSF) analysis showed 4 lymphocytes per microliter and normal levels of the protein and sugar. The tests for bacterial, fungal, and tubercular infections were negative. The patient had a family history of diabetes mellitus, and HbA1c at admission was 8.61 g/dL. The tests for HIV-1 and -2 were negative.
Over the next 15 days, the patient also developed left hemiparesis, followed by severe diffuse headache, vomiting, and a sensorial decline. Urgent decompressive craniectomy was performed.

Histopathological examination of the brain biopsy revealed the presence of necrotic tissue with inflammation and numerous amoebic trophozoites (Figure 1B). The tests for serum anti-Toxoplasma IgG and anti-herpes simplex virus (HSV) IgM were positive. However, Toxoplasma cysts or tachyzoites were not detected by histopathological examination, and the polymerase chain reaction (PCR) test for HSV in the CSF was negative.

The patient did not have any previous history of amoebic keratitis, use of contact lenses, or fresh-water swimming. A test for immunodeficiency revealed normal activities of NK, T, and B cells and slightly reduced neutrophil oxidative index (i.e., 75). The absolute count of CD4-positive T cells was decreased (299/μL). Pending the confirmation of the presence of specific free-living amoeba, the patient was empirically administered a six-drug regimen, including liposomal amphotericin B (3 mg/kg/day), trimethoprim-sulfamethoxazole (TMP-SMX) (160 mg/800 mg per day), fluconazole (800 mg/day), albendazole (400 mg/day), azithromycin (500 mg/day), and rifampicin (600 mg/day). However, the patient developed Stevens-Johnson syndrome due to TMP-SMX, and the drug treatment was thus stopped. Flucytosine was added at a dose of 40 mg/kg/day. Continuous electroencephalogram showed features consistent with nonconvulsive status epilepticus. The condition was managed by intravenous infusion of midazolam for 24 hours and up-titration of anti-epileptics.

Aspiration of the scalp swelling revealed acanthamoeba cysts detected by lactophenol cotton blue staining. PCR for 18S ribosomal deoxyribonucleic acid (DNA) with the JDP primer confirmed the diagnosis. DNA was extracted using a QIAGEN test kit.

Miltefosine was added to the regimen at a dose of 50 mg thrice daily and was continued for four weeks. The patient did not show any further improvement over the next four weeks; contrast-enhanced MRI of the brain was repeated, and the images showed an organizing abscess within central necrotic tissue and a surrounding enhancing rim (Figure 1C). A surgical procedure was performed to excise the abscess.

Another histopathological examination of the brain biopsy revealed multiple acanthamoeba trophozoites, as confirmed by PCR.

After debridement, the sensorium of the patient gradually improved, and repeated imaging of the brain revealed a significant decrease in the mass effect (Figure 1D).

After 15 weeks of hospital stay, the patient was finally discharged in a hemodynamically stable tracheostomized state with a Glasgow coma score of E4V6M6 on five anti amoebic drugs, including flucytosine, fluconazole, rifampicin, azithromycin, and albendazole. The patient is being followed up by telephone due to the current COVID-19 surge. The patient is doing well at home eight weeks after discharge from the hospital.

Discussion

Infection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) predisposes patients to secondary infections in a number of ways, including immune dysregulation and treatment-related factors, such as the use of corticosteroids. SARS CoV-2 inhibits the type I interferon signaling pathway and attenuates the innate immune response (Li et al., 2020; Schreiber, 2020). COVID-19 is also characterized by the presence of dysfunctional mature neutrophils and neutrophil precursors and exhaustion of CD4- and CD8-positive T cells (Caserta et al., 2019; Schulte-Schrepping et al., 2020). In the patient described in the present study, both absolute CD4 count and neutrophil oxidative index were reduced on the seventh week of the illness. These effects can be a mechanism by which the patient developed acanthamoeba encephalitis following COVID-19 illness, in addition to diabetes mellitus, which was newly detected.

The treatment regimen used to treat the patient consisted of a combination of trophicidal agents (miltefosine, fluconazole, flucytosine, and azithromycin), cysticidal agents (miltefosine and fluconazole), and other agents that have been previously used to treat the survivors of acanthamoeba encephalitis (Alli et al., 2021; Elsheikha et al., 2020; Fischman et al., 1993; Id et al., 2020).

Caspofungin at a maintenance dose of 50 mg/day was administered to the patient for 34 days to treat candidaemia caused by...
Candida auris. This agent has also been shown to have triphasic and cytoidal activities against acanthamoebae in vitro (Bouyer et al., 2007).

Amphotericin B is the cornerstone therapy against Naegleria in primary amoebic meningoencephalitis; however, there is little evidence for the use of this drug in acanthamoebic encephalitis. The drug has been discontinued after the presence of the etiological agent in the patient was confirmed by PCR.

Considering the changes detected by MRI of the brain before and after the treatment with miltefosine, the drug apparently had the maximum effect in the studied case. Acanthamoeba castellani is highly sensitive to miltefosine in vitro, whereas Acanthamoeba lugdunensis and other species have low sensitivity to the drug even at higher concentrations (Mrva et al., 2011). The concentration of miltefosine achieved in the human brain parenchyma is yet to be determined.

The lesions began to organize following the combination medical therapy with miltefosine; however, the patient’s sensorium further improved only after surgical excision of the abscess. This approach has been rarely used previously in the survivors but should be considered whenever feasible.

Conclusion

Acanthamoebic encephalitis should be considered when patients present with neurological deficits and brain lesions, which rapidly progress and cause mass effects. The best approach to the management involves a combination of medical and surgical inter-ventions. Randomized clinical trials are needed to standardize the treatment for acanthamoebic encephalitis, and the role of COVID-19 in predisposition of the patients to this infection needs to be evaluated.

Competing interests

The authors declare that they have no known competing interests that influenced the work reported in this paper.

Funding source

This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments

We thank Dr MC Sharma for the expert review of the histopathology specimens, Dr BR Mirdha for the microbiological analyses and PCR tests, Dr Manish Soneja for his valuable input in medical therapy and Dr Mannmohan Singh for skillful surgical intervention. We also thank all the members of faculty of the department of neurology and all the doctors and other staff involved in caring for this patient.

Ethical approval

Next of kin of the patient described in the study gave consent to publish the history and images of the investigation anonymously.

References

Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis | Acanthamoeba | Parasites | CDC. n.d. https://www.cdc.gov/parasites/acanthamoeba/index.html (accessed June 6, 2021).
Alli A, Ortiz JF, Morillo Cox A, Armas M, Orellana VA. Miltefosine: A Miracle Drug for Meningoencephalitis Caused by Free-Living Amoebae. Cures 2021;13. doi:10.7759/cures.13698.
Bouyer S, Imbert C, Danault G, Cateau E, Rodier MH. Effect of caspofungin on trophozoites and cysts of three species of Acanthamoeba. J Antimicrob Chemother 2007;59:122–4. doi:10.1093/jac/dkl451.
Brandley N, Matin A, Khan NA. Acanthamoeba castellani: High antibody prevalence in racially and ethnically diverse populations. Exp Parasitol 2009;121:254–6. doi:10.1016/j.exppara.2008.11.009.
Caserta S, Maria Terrazzini N, Borger J, Wu Y, Chen Y, Diao B, et al. Article 827 (2020) Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol 2019;11:827. doi:10.3389/fimmu.2020.00827.
Elsheshia HM, Siddiqi R, Khan NA. Drug discovery against acanthamoeba infections: Present knowledge and unmet needs. Pathogens 2020;9:405. doi:10.3390/pathogens9050405.
Fischman AJ, Alipert NME, Livni E, Ray S, Sinclair I, Callahan RJ, et al. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 1993;37:1270–7. doi:10.1128/AAC.37.6.1270.
Id CAR, Colon ID, Chen E, Hull ID M Y, Kyleid DE. Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae 2020. https://doi.org/10.1371/journal.pntd.0008353.
Kot K, Łanocha-Arendarczyk N, Kosik-Bogacka D. Immunopathogenicity of acanthamoeba spp. In the brain and lungs. Int J Mol Sci 2021;22:1–21. doi:10.3390/ijms22031261.
Kot K, Łanocha-Arendarczyk NA, Kosik-Bogacka DI. Amoebas from the genus Acanthamoeba and their pathogenic properties. Ann Parasitol 2018;64:299–308. doi:10.17420/ap6454.164.
Li JY, Liao CH, Wang Q, Tan YJ, Luo R, Qiu Y, et al. The ORFs, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res 2020;286. doi:10.1016/j.virusres.2020.190874.
Mrva M, Garajová M, Lukác M, Öndráška F. Weak cytotoxic activity of miltefosine against clinical isolates of Acanthamoeba spp. J Parasitol 2011;97:538–40. doi:10.1645/GE-2669.1.
Schreiber G. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Front Immunol 2020;11:2599. doi:10.3389/fimmu.2020.595739.
Schulte-Schrepping J, Reusch N, Paclick D, Baßler K, Schliekiser S, Zhang B, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell 2020;182:1419–1440.e23. doi:10.1016/j.cell.2020.08.001.